Finerenone (Kerendia) for Chronic Kidney Disease

Date: August 23, 2021 Issue #:  1631Summary:  Finerenone (Kerendia– Bayer), an oral nonsteroidal mineralocorticoid receptor antagonist (MRA), has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage renal disease, nonfatal MI, hospitalization for heart failure (HF), and cardiovascular death in adults with chronic kidney disease (CKD) associated with type 2 diabetes. It is the first nonsteroidal MRA to be approved in the US.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: ACE inhibitors ARBs chronic kidney disease finerenone Hypertension Kerendia type 2 diabetes Source Type: research